Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Development of a flow cytometry assay which allows to evaluate the efficiency of immunomodulatory vaccines to enhance T cell-mediated antitumor response

Texto completo
Autor(es):
Manrique-Rincon, Andrea J. [1, 2] ; de Carvalho, Anna C. [1] ; Eugenia Ribeiro de Camargo, M. [1] ; Franchini, Kleber G. [1, 2] ; Bajgelman, Marcio C. [3, 1, 2]
Número total de Autores: 5
Afiliação do(s) autor(es):
[1] Brazilian Biosci Natl Lab, Ctr Res Energy & Mat, Rua Giuseppe Maximo Scolfaro 10-000, BR-13083100 Campinas, SP - Brazil
[2] Univ Estadual Campinas, Sch Med, Campinas, SP - Brazil
[3] Univ Estadual Campinas, Inst Biol, Campinas, SP - Brazil
Número total de Afiliações: 3
Tipo de documento: Artigo Científico
Fonte: Journal of Biotechnology; v. 284, p. 11-16, OCT 20 2018.
Citações Web of Science: 1
Resumo

Immunotherapy has revolutionized the treatment of cancer. Since tumor cells exhibit low immunogenicity and can induce several mechanisms of tolerance, the use of monoclonal antibodies or other immunomodulators, targeting costimulation of T cells may mediate the inhibition of immunosuppressive mechanisms, favouring immune surveillance and enhancing the detection and elimination of tumor cells. We developed a new in vitro assay, based on flow cytometry, which allows exploring the therapeutic potential of tumor-derived immunomodulatory lineages, enhancing anti-tumor response. We generated tumor-derived cells that simultaneously co-express eGFP and one immunomodulatory molecule (OX40L, 4-1BBL or GM-CSF). These genetically modified tumor-derived cells are irradiated and then incubated with primary T cells to evaluate the killing activity, which can be estimated by a decrease in the eGFP positive cells. The results have shown correlation with in vivo experiments. This model may contribute to the development of high-throughput assays for the screening of immunomodulators and a reduction in the use of experimental animals. (AU)

Processo FAPESP: 17/06692-2 - Desenvolvimento de novos receptores de células T a partir do isolamento de sequências obtidas de linfócitos infiltrados em sítios tumorais, provenientes de animais tratados com imunomoduladores
Beneficiário:Marcio Chaim Bajgelman
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 13/02041-6 - Desenvolvimento de uma estratégia de silenciamento transcricional do fator FoxP3 com alvo de inativar células T regulatórias e potenciar resposta imune antitumoral
Beneficiário:Andrea Johanna Manrique Rincón
Linha de fomento: Bolsas no Brasil - Doutorado Direto